The Fractional Leadership Operating Model for Series B Biotechs

Why Fractional Works at Series B

The Series B window is structurally distinctive. A typical Series B biotech has raised $40 million to $100 million, has 30 to 80 employees, has at least one program in active development, and has a clear thesis for the next 18 to 30 months of work. The company needs senior leadership across most major functions, but the workload in each function is variable: regulatory affairs intensifies dramatically around an IND submission and quiets between regulatory inflection points; CFO work spikes during fundraising and quiets between rounds; CIO work spikes during platform builds and quiets during steady-state operations.

A full-time C-suite hire in any of these functions makes sense when the workload is consistently full-time and when the strategic stakes justify the cash burn. At Series B, this is often not the case. The workload is real but not consistently full-time, and the cash burn of a full-time executive (typically $400K to $700K all-in, with equity that further dilutes founders and early investors) is a meaningful drag on runway. Fractional executives at $15K to $30K per month, deployed two to six days per month, provide most of the senior leadership value at a fraction of the burn.

The other factor is risk calibration. Full-time C-suite hires are sticky: replacing a misfit takes 6 to 12 months and produces meaningful organizational disruption. Fractional engagements can be adjusted in days. For a Series B biotech navigating early product-market or platform-validation questions, the optionality of fractional engagement is itself valuable, even before the cash savings are considered.

Boards have warmed to the model significantly over the past five years. The legacy resistance — that a “real” company needs full-time C-suite executives — has eroded as the model has demonstrated itself across hundreds of Series B and Series C biotechs. The BioSpace industry coverage and the Endpoints News reporting both routinely document fractional and interim executive arrangements at companies that subsequently move through later financings without difficulty.

What to Fractionalize (and What Not to)

Not all senior leadership functions are equally suitable for fractionalization at Series B. The functions where the model consistently works:

The functions that fractionalize well share a common pattern: they require senior judgment, the workload is episodic rather than continuous, the function does not define the company’s scientific identity, and the work can be executed effectively from outside the day-to-day operational core. CFO, CIO, CISO, and regulatory affairs all fit this pattern at Series B.

The functions that resist fractionalization share the opposite pattern: they define the company’s identity, the workload is continuous, and effectiveness requires deep daily integration with the science. CSO and CMO/Head of Clinical are the canonical examples. Trying to fractionalize these functions almost always produces a structural mismatch that becomes evident within 6 to 12 months.

The middle cases — head of HR/people, head of business development — depend more on the specific company. Some Series B biotechs successfully fractionalize HR; others find that the people function needs full-time leadership to support the rapid headcount growth that often characterizes the Series B to Series C transition.

Governance: Reporting Lines and Decision Rights

The most common failure mode in fractional engagements is ambiguity about decision rights. A fractional CFO who has no clear authority to commit on financial controls, or a fractional CIO who has no clear authority to make technology vendor decisions, will produce frustration on both sides within months. The cure is explicit governance, documented in the engagement letter and reaffirmed at the first board meeting following the engagement’s start.

The reporting line should be to the CEO, treated identically to a full-time executive in the same function. This is non-negotiable. Fractional executives who report to other executives (the COO, the CFO for a CIO role, the CSO for a head of regulatory) are positioned as advisors rather than as leaders, and the function suffers accordingly. The CEO may delegate operational oversight to another executive on a day-to-day basis, but the formal reporting line and decision rights should sit at the CEO level.

Decision rights should be articulated explicitly. The fractional executive should have the same authority as a full-time executive in the same function up to a defined dollar threshold (typically $50K to $250K depending on the function and the company’s scale), with anything above the threshold requiring CEO sign-off. Vendor selection, hiring within the function, and policy decisions within the function should sit with the fractional executive. Strategic posture (major platform decisions, major regulatory pathway decisions) should be co-developed with the CEO and ratified at the board level.

Board-level visibility should be explicit. The fractional executive should attend board meetings as a member of the executive team, present in their function area, and be available for board director questions outside the meeting. Hiding the fractional nature of the engagement from the board produces credibility risk down the line; treating it as a normal part of the operating model produces durable board trust. The BCG biopharmaceuticals practice has documented this pattern across multiple biotech CEO transitions.

Integration Patterns That Actually Work

The single biggest predictor of fractional engagement success is the integration pattern with the rest of the leadership team. Three patterns work consistently.

The dedicated day pattern. The fractional executive is on-site or fully available one specific day per week (typically Tuesday or Wednesday), with that day used for all major function meetings, decision-making sessions, and direct reports’ one-on-ones. The rest of the week is available for asynchronous work and emergencies. This pattern creates predictable rhythm and lets the rest of the organization plan around the executive’s availability.

The sprint pattern. The fractional executive is dedicated to specific high-intensity periods (a fundraise for a CFO, an IND submission for a regulatory leader, a platform build for a CIO), with lower-intensity baseline availability between sprints. This pattern works particularly well for functions where the workload is genuinely episodic.

The hybrid pattern. A combination of the two, with a baseline dedicated day plus additional capacity during sprints. This is the most common pattern in well-run Series B biotechs because it accommodates both the predictable rhythm needs and the episodic spikes.

Cadence and Capacity Calibration

Fractional capacity needs ongoing calibration. The initial engagement should be sized to expected workload, with a defined check-in cadence (typically quarterly) to assess whether the capacity is matching reality. Three patterns of misalignment require attention.

Under-capacity. The fractional executive is consistently working more than the agreed days, either invoicing for the overage or absorbing it as goodwill. Sustainable arrangements require renegotiating the engagement to match the actual workload, either by adding capacity or by reducing scope. Goodwill absorption is not sustainable and often produces resentment that surfaces months later as engagement quality declines.

Over-capacity. The fractional executive has unused days, and the company is paying for capacity that is not being used. Sustainable arrangements require either reducing the engagement size or expanding scope to use the capacity productively. Some companies use over-capacity to add adjacent scope (a fractional CIO with extra capacity taking on data and analytics oversight, for example); others reduce the engagement and reallocate the capital.

Spike mismatch. The baseline engagement is appropriately sized, but spikes are not adequately accommodated. The fix is to articulate sprint terms in advance, with defined trigger events (fundraise launch, IND filing decision, audit scheduling) that activate additional capacity at pre-agreed rates. Sprint terms reduce the friction of mid-engagement renegotiation when a spike is in progress and the parties are stressed.

The quarterly check-in is the operating mechanism that keeps the capacity calibration honest. The check-in should review actual time spent versus engagement terms, satisfaction on both sides, scope alignment, and any adjustments needed. Companies that skip this discipline tend to drift into one of the three misalignment patterns within 18 months.

The Failure Modes That Derail the Model

Several failure modes show up repeatedly in fractional engagements that go badly. Understanding them up front is the most reliable way to avoid them.

Treating the fractional executive as a contractor. When the engagement is structured purely transactionally — defined deliverables, no executive team integration, no board visibility — the fractional executive functions as a contractor, not as a leader. The work product may be fine, but the leadership value is lost. This is the most common failure mode and the most expensive, because it leaves the company paying for senior leadership and receiving senior consulting.

Ambiguous decision rights. When the fractional executive’s authority is undefined, every decision becomes a negotiation. Velocity suffers, and the fractional executive’s frustration eventually catalyzes either disengagement or departure. Explicit decision rights documented in the engagement letter are the cure.

Over-fractionalization. Some Series B biotechs deploy fractional executives in every function, including functions that should not be fractionalized (CSO, CMO, head of clinical). The result is a leadership team without core, where no executive has the daily integration with the science that the most strategic decisions require. The fix is to be disciplined about which functions to fractionalize.

Hidden fractional status. When the company conceals the fractional nature of the engagement from board members, partners, or investors, credibility risk accumulates. The cure is transparency. Fractional engagements are a normal part of the Series B operating model, and presenting them as such produces durable trust.

Inadequate transition planning. When the time comes to transition a fractional role to full-time, companies that have not planned for the transition find themselves either retaining the fractional engagement too long (paying full-time-equivalent rates without full-time integration) or rushing the transition in ways that produce continuity gaps. The transition should be planned 6 to 12 months in advance.

The Transition to Full-Time Leadership

Every fractional engagement eventually transitions, either to a full-time hire in the function or to a continued fractional arrangement at adjusted scope. The transition is itself a moment of organizational risk, and the companies that manage it well share a pattern.

The trigger for the transition is typically workload. When the fractional capacity is consistently being exceeded, when the function needs daily integration that the fractional schedule cannot provide, or when the strategic stakes have escalated to the point where part-time leadership is no longer defensible, the transition to full-time becomes the right move. The decision should be made at the board level, with input from the fractional executive on whether they are interested in the full-time role and on what the successor profile should look like if they are not.

If the fractional executive becomes the full-time executive, the transition is relatively clean. Capacity expands, integration deepens, and the engagement converts to a full-time employment relationship with appropriate compensation and equity. This pattern is common in well-run engagements where the fit has proved out over 12 to 24 months.

If the fractional executive does not become the full-time executive, the transition requires more deliberate work. The fractional executive should be involved in the successor search, the knowledge transfer should be structured (typically 8 to 12 weeks of overlap), and the relationship after departure should be defined (often a continuing advisory role with much-reduced capacity). Companies that botch this transition produce continuity gaps that damage the function for 6 to 12 months; companies that manage it well preserve institutional knowledge and maintain the function’s velocity through the transition.

Compensation, equity, and the economics of the model

The economics of fractional engagements are an important dimension that deserves explicit discussion. Cash compensation for fractional executives in Series B biotechs typically runs $15K to $30K per month depending on the function, the executive’s seniority, and the capacity. This is meaningful capital but materially less than a full-time hire at the same level. Equity arrangements vary widely: some engagements include no equity (cash-only), others include modest equity grants vesting over the engagement period, and still others include equity arrangements that anticipate the transition to a full-time role.

The economic case for the model is straightforward at Series B but evolves as the company scales. At Series B, fractional engagements typically save 50 to 70 percent of the all-in cost of a full-time hire while delivering 60 to 90 percent of the leadership value in the function. As the company moves toward Series C and beyond, the marginal value of additional leadership integration grows, and the case for full-time hires strengthens. The transition window is typically the Series C to Series D inflection, where companies that maintained fractional engagements through Series B begin converting them to full-time roles as the workload, complexity, and stakes catch up to the cost of full-time leadership. Companies that anticipate this trajectory and plan their engagement structure with the transition in mind end up significantly better positioned than companies that treat each engagement as if it will last forever.

References & Sources